Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

We are excited about the opportunity to extend Dupixent's leadership in respiratory ... glad to be flattered by Amgen that they're spending their time imitating our products.

The Committee for Medicinal Products for Human Use (CHMP ... The main issue for the company is that Amgen’s rival KRAS inhibitor Lumykras (sotorasib) has already been given conditional approval ...

Also, Pfizer acknowledged the firm would be unlikely to hit the previous 6% growth-rate guidance from 2020 to 2025 (excluding COVID-19 products ... more robust fall respiratory season.

The stock market retreated this week amid earnings from Microsoft, Amazon, Meta, Apple, Google and many more, along with preelection jitters.

Read also: Roche launches cobas Respiratory flex test to detect up to 12 most common ... The advocacy groups said at the time that the deal could constrain competitors such as Amgen, opens new tab, ...

In a report to investors this week, Guggenheim Securities analysts said they see Pfizer as a winner with “significant upside potential” to consensus numbers based on increased demand for COVID-19 ...